Boston, MANCT07560306Now EnrollingIRB Ready

Cardiac Amyloidosis Clinical Trial in Boston, MA

Access cutting-edge cardiac amyloidosis treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Brigham and Women's Hospital

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access cardiac amyloidosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cardiac amyloidosis treatment provided free

Apply for This Boston Location

Check if you qualify for this cardiac amyloidosis clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Cardiac Amyloidosis Study in Boston

The primary goal of this pilot study is to determine whether \[64Cu\]FBP8, a novel fibrin-binding positron emission tomography (PET) probe, can identify intracardiac thrombi when paired with simultaneous hybrid cardiac PET/MRI in twenty (20) individuals with transthyretin or light chain cardiac amyloidosis and atrial fibrillation (AF) or atrial flutter (AF). The primary hypothesis of this study is that \[64Cu\]FBP8 PET/MRI can identify intracardiac thrombi in \>90% of subjects with confirmed intracardiac thrombi based on transesophageal echocardiogram (TEE). In secondary analyses, the investigators will seek to determine associations between intracardiac thrombi and left atrial function and left ventricular amyloid burden.

Sponsor: Brigham and Women's Hospital

Who Can Participate

Inclusion Criteria

Have the ability to give written informed consent;
History of amyloid cardiomyopathy (ATTR-CM or AL-CM);
History of AF or AFL;
Retrospective enrollment: TEE to evaluate LAA within the previous 14 days, provided the anticoagulation regimen the patient is on is not changed after the TEE. If a patient has a negative TEE and continues the same stable anticoagulation regimen, then it is unlikely that a new thrombus will develop in the LAA within the next 14 days. Likewise, if a patient not taking any anticoagulation has a thrombus in the LAA, then it is unlikely that this thrombus will resolve spontaneously in the next 14 days if the patient remains off anticoagulation. If the TEE leads to a change being made in the anticoagulation regimen (started/stopped/dose modified), then a time window of 72 hours from the TEE to PET/MR imaging will be used. This scheme will ensure that the TEE can serve as an accurate gold standard;
Prospective: TEE to evaluate LAA thrombus scheduled in upcoming 14 days;

Exclusion Criteria

Electrical implants such as cardiac pacemaker/defibrillator, perfusion pump, direct brain stimulator;
Pregnancy or breastfeeding (a negative quantitative serum or urine hCG pregnancy test is required for females having child-bearing potential before the subject can participate);
Claustrophobia;
Subjects will be excluded if research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months);
Unable to lie comfortably on a bed inside the PET/MR scanner;
Subjects under direct or indirect (i.e., same department as PIs) supervision of the principal investigator;
Body weight over the weight limit for the moving table (\> 300 lbs for the MR table);
Metallic or electric implants contraindicated for PET/MR scanning;
Stroke, myocardial infarction, cardiac or major surgery within the last 3 months;
History of LAA ligation/exclusion or presence of a LAA occlusion device;
History of syncope within the last 6 weeks;
Heart rate persistently \>120 bpm or persistently \<50 bpm;
Daytime pauses \>3 seconds;
Lack of a prior transthoracic echocardiogram within the previous 6 months;
Does not have the ability to give written informed consent;
Determined by the investigator(s) to be clinically unsuitable for the study (e.g., based on screening visit and/or during study procedures);

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT07560306) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cardiac Amyloidosis Treatment Options in Boston, MA

If you're searching for cardiac amyloidosis treatment options in Boston, MA, this clinical trial (NCT07560306) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cardiac amyloidosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cardiac amyloidosis clinical trials near you to find additional studies recruiting in your area.

More Amyloidosis Trials in Boston, MA

See all amyloidosis clinical trials recruiting in Boston — not just this study.

Browse Amyloidosis Trials in Boston →

Browse More Trials by Condition

Amyloidosis TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA